Protecting the ischaemic and reperfused myocardium in acute myocardial infarction: Distant dream or near reality?

Heart

Volumn 83, Issue 4, 2000, Pages 381-387

  Yellon, D M ^a   Baxter, G F ^a  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE; ADENOSINE RECEPTOR; ANTITHROMBOCYTIC AGENT; BRADYKININ; BRADYKININ B2 RECEPTOR; CARDIOTROPHIN 1; CARIPORIDE; DIAZOXIDE; DIPEPTIDYL CARBOXYPEPTIDASE; MAGNESIUM; NICORANDIL; OPIATE PEPTIDE; PROTECTIVE AGENT; TRANSFORMING GROWTH FACTOR BETA1;

ACUTE HEART INFARCTION; CLINICAL TRIAL; CORONARY ARTERY BLOOD FLOW; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY DILATATION; FIBRINOLYTIC THERAPY; HEART MUSCLE ISCHEMIA; HEART MUSCLE REPERFUSION; HEART PROTECTION; HUMAN; NEUTROPHIL; PRIORITY JOURNAL; PROTON SODIUM EXCHANGE; REPERFUSION INJURY; REVIEW; SODIUM CALCIUM EXCHANGE; UNSTABLE ANGINA PECTORIS;

EID: 0034024355     PISSN: 13556037     EISSN: None     Source Type: Journal    
DOI: 10.1136/heart.83.4.381     Document Type: Review

References (53)

1. Lopez AD, Murray CCJL. The global burden of disease, 1990-2020. Nature Med 1998;4:1241-3
2. Simmons WW, Armstrong PW. Thrombolytic therapy in acute myocardial infarction. Curr Opin Cardiol 1993;8:604-12.
3. Anderson HV, Willerson JT. Current concepts: thrombolysis in acute myocardial infarction. N Eng J Med 1993;329: 703-9.
4. Yellon DM, Downey JM. Current research views on myocardial reperfusion and reperfusion injury. Cardioscience 1990;1:89-98.
5. Braunwald E, Kloner RA. Myocardial reperfusion: a double-edged sword? J Clin Invest 1985;76:1713-19.
6. Opie LH. Reperfusion injury and its pharmacologic modification. Circulation 1989;80:1049-62.
7. Jennings RB, Reimer KA. Lethal reperfusion injury: fact or fancy? In: Parratt JR, ed. Myocardial response to acute injury. London: MacMillan, 1992:17-34.
8. Woods KL, Fletcher S, Roffe C, et al. Intravenous magnesium sulphate in suspected acute myocardial infarction: results of the second Leicester intravenous magnesium intervention trial (LIMIT-2). Lancet 1992;339: 1553-8.
9. ISIS-4 (Fourth International Study of Infarct Survival) Collaborative Group. ISIS-4: a randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58 050 patients with suspected acute myocardial infarction. Lancet 1995; 345:669-85.
10. Fath-Ordoubadi F, Beatt KJ. Glucose-insulin-potassium therapy for treatment of acute myocardial infarction: an overview of randomized placebo-controlled trials. Circulation 1997;96:1152-6.
11. Mahaffey KW, Puma JA, Barbagelata NA, et al. Adenosine as an adjunct to thrombolytic therapy: results of a multicenter, randomized, placebo-controlled trial: the acute myocardial infarction study of adenosine (AMISTAD) trial. J Am Coll Cardiol 1999;34:1711-20.
12. Karmazyn M. The sodium-hydrogen exchange system in the heart: its role in ishemic and reperfusion injury and therapeutic implications. Can J Cardiol 1996;12:1074-82.
13. Frolich O, Karmazyn M. The Na-H exchanger revisited: an update on Na-H exchange regulation and the role of the exchanger in hypertension and cardiac function in health and disease. Cardiovasc Res 1997;36:138-48.
14. + exchange. Basic Res Cardiol 1996;91: 203-9.
15. Gumina RJ, Mizumura T, Beier N, et al. A new sodium/hydrogen exchange inhibitor, EMD 85131, limits infarct size in dogs when administered before or after coronary artery occlusion. J Pharmacol Exp Ther 1998;286: 175-83.
16. Linz W, Albus U, Crause P, et al. Dose-dependent reduction of myocardial infarct mass in rabbits by the NHE-1 inhibitor cariporide (HOE 642). Clin Exp Hypertens 1998;20: 733-49.
17. Erhardt LRW. GUARD during ischemia against necrosis (GUARDIAN) trial in acute coronary syndromes. Am J Cardiol 1999;83:23G-25G.
18. Parratt JR. Protection of the heart by ischaemic preconditioning: mechanisms and possibilities for pharmacological exploitation. Trends Pharmacol Sci 1994;15:19-25.
19. Yellon DM, Baxter GF, Marber MS. Angina re-assessed: pain or protector? Lancet 1996;347:1059-62.
20. Przyklenk K, Kloner RA. Ischemic preconditioning: exploring the paradox. Prog Cardiovasc Dis 1998;40:517-47.
21. Yellon DM, Baxter GF, Garcia-Dorado D, et al. Ischaemic preconditioning: present position and future directions. Cardiovasc Res 1998;37:21-33.
22. Garlid KD, Paucek P, Yarov-Yarovoy V, et al. Cardioprotective effect of diazoxide and its interaction with mitochondrial ATP-sensitive K+ channels. Possible mechanism of cardioprotection. Circ Res 1997;81:1072-82.
23. Liu Y, Sato T, O'Rourke B, et al. Mitochondrial ATP-dependent potassium channels: novel effectors of cardioprotection? Circulation 1998;97:2463-9.
24. Wang J, Drake L, Sajjadi F, et al. Dual activation of adenosine A1 and A3 receptors mediates preconditioning of isolated cardiac myocytes. Eur J Pharmacol 1997;320:241-8.
25. Liu GS, Thornton J, Van Winkle DM, et al. Protection against infarction afforded by preconditioning is mediated by adenosine A1 receptors in rabbit heart. Circulation 1991;84:350-6.
26. Tracey WR, Magee W, Masamune H, et al. Selective adenosine A3 receptor stimulation reduces ischemic myocardial injury in the rabbit heart. Cardiovasc Res 1997;33:410-15.
27. Walker DM, Walker JM, Pugsley WB, et al. Preconditioning in isolated superfused human muscle. J Mol Cell Cardiol 1995;27:1349-57.
28. Carr CS, Hill RJ, Masamune H, et al. Evidence for a role for both the adenosine A1 and A3 receptors in protection of isolated human atrial muscle against simulated ischaemia. Cardiovasc Res 1997;36:52-9.
29. Dana A, Baxter GF, Walker JM, et al. Prolonging the delayed phase of myocardial protection: repetitive adenosine A1 receptor activation maintains rabbit myocardium in a preconditioned state. J Am Coll Cardiol 1998;31:1142-9.
30. Travers A, Middlemiss D, Louttit JB. Cardioprotection after repeated dosing with GR79236, an adenosine A1 agonist [abstract]. Br J Pharmacol 1998;124(suppl):102P.
31. Goto M, Liu Y, Yang XM, et al. Role of bradykinin in protection of ischemic preconditioning in rabbit hearts. Circ Res 1995;77:611-21.
32. Wall TM, Sheehy R, Hartman JC. Role of bradykinin in myocardial preconditioning. J Pharmacol Exp Ther 1994; 270:681-9.
33. Parratt JR, Vegh A, Papp JG. Bradykinin as an endogenous myocardial protective substance with particular reference to ischemic preconditioning - a brief review of the evidence. Can J Physiol Pharmacol 1995;73:837-42.
34. Heusch G, Rose J, Ehring T. Cardioprotection by ACE inhibitors in myocardial ischaemia/reperfusion. The importance of bradykinin. Drugs 1997;54(suppl 5):31-41.
35. Schultz JJ, Hsu AK, Gross GJ. Ischemic preconditioning and morphine-induced cardioprotection involve the d-opioid receptor in the intact rat heart. J Mol Cell Cardiol 1997;29:2187-95.
36. Tsuchida A, Miura T, Tanno M, et al. Time window for the contribution of the delta-opioid receptor to cardioprotection by ischemic preconditioning in the rat heart. Cardiovasc Drugs Ther 1998;12:365-73.
37. Aitchison KA, Baxter GF, Yellon DM, et al. Involvement of delta opioid receptor subtype in ischaemic preconditioning against infarction in isolated rat heart [abstract]. Br J Pharmacol 1998;124(suppl):22P.
38. Schultz JJ, Hsu AK, Nagase H, et al. TAN-67, a delta 1-opioid receptor agonist, reduces infarct size via activation of Gi/o proteins and KATP channels. Am J Physiol 1998;274:H909-14.
39. Schultz JEJ, Hsu AK, Gross GJ. Morphine mimics the cardioprotective effect of ischemic preconditioning via a glibenclamide-sensitive mechanism in the rat heart. Circ Res 1997;78:1100-4.
40. McCormack KJ, Chapleo CB. Opioid receptors and myocardial protection. Clin Drug Invest 1998;15:445-54.
41. Sato T, Sasaki N, O'Rourke B, et al. Nicorandil activates miotchondrial ATP-dependent potassium channels in rabbit ventricular cells [abstract]. Circulation 1998;98(suppl): 1-343.
42. Imagawa J, Baxter GF, Yellon DM. Myocardial protection afforded by nicorandil and ischaemic preconditioning in a rabbit infarct model in vivo. J Cardiovasc Pharmacol 1998; 31:74-9.
43. Mizumura T, Nithipatikom K, Gross GJ. Infarct-size reducing effect of nicorandil is mediated by the KATP channel but not by its nitrate-like properties in dogs. Cardiovasc Res 1996;32:274-85.
44. Patel DJ, Purcell HJ, Fox KM. Cardioprotection by opening of the KATP channel in unstable angina. Is this a clinical manifestation of myocardial preconditioning? Results of a randomized study with nicorandil. Eur Heart J 1999;20:51-7.
45. Bartling B, Holtz J, Darmer D. Contribution of myocyte apoptosis to myocardial infarction? Basic Res Cardiol 1998; 93:71-84.
46. Fliss H. Accelerated apoptosis in reperfused myocardium: friend or foe? Basic Res Cardiol 1998;93:90-3.
47. Jonassen AK, Brar BK, Mjos OD, et al. Insulin modifies myocyte apoptosis and reduces myocardial infarct size when administered at reperfusion: a novel mechanism of protection [abstract]. Br J Pharmacol 1999;126(suppl): 201P.
48. Cai Q, Brar B, Stephanou A, et al. Cardiotrophin-I reduces infarct size in an isolated rat heart model via a MAP kinase depednent pathway [abstract]. J Physiol 1999;518P:16P.
49. Mocanu MM, Baxter GF, Yellon DM. Transforming growth factor-β1 limits infarct size when administered prior to reperfusion in an isolated rat heart model [abstract]. Br J Pharmacol 1999;126(suppl):198P.
50. Yaoita H, Ogawa K, Maehara K, et al. Attenuation of ischemia/reperfusion injury in rats by a caspase inhibitor. Circulation 1998;97:276-81.
51. Ruetten H, Gehring D, Busch A. Caspase inhibitors improve post-ischaemic functional recovery in rat isolated working hearts. Br J Pharmacol 1999;126(suppl):200P.
52. Endres M, Namura S, Shimizu-Sasamata M, et al. Attenuation of delayed neuronal death after mild focal ischemia in mice by inhibition of the caspase family. J Cereb Blood Flow Metab 1998;18:238-47.
53. Mocanu MM, Baxter GF, Yellon DM. Caspase inhibition at reperfusion protects the isolated rat heart. Circulation 1999;100(suppl):I-10.